Aging
Navigate
Research Paper|Volume 12, Issue 5|pp 4178—4192

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

Xiaojun Feng1, Yanan Wang2, Wenxu Chen2, Suowen Xu3, Lingli Li1, Yadi Geng1, Aizong Shen1,4, Hui Gao5, Lei Zhang1, Sheng Liu1
  • 1The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR. China
  • 2Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, PR. China
  • 3Aab Cardiovascular Research Institute, University of Rochester, West Henrietta, NY 14586, USA
  • 4Anhui Provincial Cardiovascular Institute, Hefei, Anhui, PR. China
  • 5Department of Pharmacology, School of Medicine, Shaoxing University, Shaoxing, PR. China
* Equal contribution
Received: June 4, 2019Accepted: January 24, 2020Published: March 4, 2020

Copyright © 2020 Feng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Sirtuin 3 (SIRT3) is a type III histone deacetylase that inhibits cardiac hypertrophy. It is mainly localized in the mitochondria and is thus implicated in mitochondrial metabolism. Recent studies have shown that SIRT3 can also accumulate in the nuclear under stressed conditions, and participated in histone deacetylation of target proteins. Poly [ADP-ribose] polymerase 1 (PARP-1) functions as an important PARP isoform that was involved in cardiac hypertrophy. Our experiments showed that SIRT3 accumulated in the nuclear of cardiomyocytes treated with isoproterenol or SIRT3 overexpression. Moreover, overexpression of SIRT3 by adenovirus inhibited the expression of cardiac hypertrophic genes-ANF and BNP, as well as abrogating PARP-1 activation induced by isoproterenol or phenylephrine. In addition, co-immunoprecipitation experiments revealed that SIRT3 could interact with PARP-1, and overexpression of SIRT3 could decrease the acetylation level of PARP-1. Our results indicate that SIRT3 exerts protective effects against cardiac hypertrophy by reducing the level of acetylation and activity of PARP-1, thus providing novel mechanistic insights into SIRT3-mediated cardiprotective actions.